Zizant 2MIU Injection contains Colistimethate Sodium equivalent to 2 million International Units (IU) and is indicated for the treatment of serious infections caused by susceptible strains of gram-negative bacteria, particularly multidrug-resistant Pseudomonas aeruginosa. Colistimethate Sodium is a polymyxin antibiotic that acts by disrupting the bacterial cell membrane, leading to cell death. This injectable formulation is primarily used in hospital settings for infections such as ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and complicated intra-abdominal infections when alternative therapies are ineffective or contraindicated. Dosage and duration of therapy should be individualized based on the severity of infection, renal function, and patient response. Zizant 2MIU Injection is administered via intravenous infusion under strict aseptic conditions. Caution is advised in patients with renal impairment, as dose adjustment may be necessary to minimize the risk of nephrotoxicity and neurotoxicity, which are the most significant adverse effects associated with colistimethate sodium. Monitoring of renal function and neurological status is recommended during therapy. This product should be used under the supervision of a qualified healthcare professional experienced in the management of serious bacterial infections.